Gross Profit Comparison: Walgreens Boots Alliance, Inc. and Halozyme Therapeutics, Inc. Trends

Comparing Profit Trends: Walgreens vs. Halozyme

__timestampHalozyme Therapeutics, Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 20145260200021569000000
Thursday, January 1, 201510581200026753000000
Friday, January 1, 201611348500029874000000
Sunday, January 1, 201728546100029162000000
Monday, January 1, 201814172600030792000000
Tuesday, January 1, 201915044600028159000000
Wednesday, January 1, 202022422700026077000000
Friday, January 1, 202136189700028067000000
Saturday, January 1, 202252081200028266000000
Sunday, January 1, 202363689200027072000000
Monday, January 1, 202485590700026524000000
ngram

Gross Profit Trends: Walgreens Boots Alliance vs. Halozyme Therapeutics

In the ever-evolving landscape of the pharmaceutical and healthcare sectors, understanding financial trends is crucial. Over the past decade, Walgreens Boots Alliance, Inc. has consistently demonstrated robust financial health, with gross profits peaking at approximately $30.8 billion in 2018. Despite a slight decline in recent years, Walgreens maintains a strong position, showcasing resilience in a competitive market.

Conversely, Halozyme Therapeutics, Inc., a smaller player, has shown impressive growth. From 2014 to 2023, Halozyme's gross profit surged by over 1,100%, reflecting its dynamic expansion and strategic advancements. This growth trajectory highlights Halozyme's potential to disrupt the market and capture significant market share.

While Walgreens' profits have seen fluctuations, Halozyme's consistent upward trend underscores the diverse opportunities within the industry. As we look to the future, these trends offer valuable insights into the strategic directions of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025